ArticleWorld journal of hepatology2026
Development and prospective validation of a machine learning model to predict mortality in cirrhosis with esophageal variceal bleeding.
Article in World journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Does Acute-on-Chronic Liver Failure Still Matter After Liver Transplantation? A Systematic Review and Meta-Analysis of One-Year Survival.Diagnostics (Basel, Switzerland) · 2026Review
- Beyond the Tipping Point: Advances in the Diagnosis and Management of Acute-on-Chronic Liver Failure and End-Stage Liver Disease.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute esophageal variceal bleeding (AEVB) is a critical complication in patients with cirrhosis, associated with high mortality despite advancements in management. Traditional prognostic scores often lack predictive accuracy in this context.
aimTo develop, internally validate, and prospectively validate a machine learning (ML) model to predict 1-year mortality in patients with cirrhosis presenting with AEVB.
methodsA retrospective cohort of 94 patients treated between 2010 and 2016 was used to train ML models, incorporating 36 clinical, laboratory, and imaging variables. Four algorithms (generalized linear models, boosted generalized linear models, naive Bayes, random forests) were evaluated, and the best-performing model was prospectively validated in a cohort of 24 patients treated between 2017 and 2018. Performance metrics included the area under the curve (AUC), sensitivity, specificity, and calibration
resultsThe random forest model achieved the highest AUC (0.91, 95% confidence interval [CI]: 0.85-0.96) during internal validation and demonstrated robust performance in the prospective cohort (AUC 0.88, 95%CI: 0.80-0.94). Calibration was excellent, with a low Brier score (0.12). The model was deployed as an online prediction tool.
conclusionThis ML model shows promise in improving mortality prediction for AEVB, potentially aiding timely clinical interventions and decision-making. Prospective validation underscores its generalizability and clinical utility. Future research should explore external validation in diverse settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.